Dr. Van Marter is the medical director of the Maternal, Fetal & Neonatal Institute and chief of Newborn Medicine at Johns Hopkins All Children’s Hospital. She joined the hospital staff in 2021. She also is a professor of Pediatrics (PAR) in the Johns Hopkins University School of Medicine.
Dr. Van Marter was most recently an associate professor of Pediatrics at Harvard Medical School and the associate chair for Academic Affairs in the Department of Pediatric Newborn Medicine at Brigham & Women’s Hospital (BWH).
Dr. Van Marter has held numerous clinical and administrative leadership roles, including as director of clinical research for the Harvard Academic Program in Newborn Medicine and, at BWH, vice chair of the Department of Pediatric Newborn Medicine and associate program director for NICU Research in the Center for Clinical Investigation.
Dr. Van Marter was first a graduate of the Massachusetts General Hospital School of Nursing, and then earned her medical degree from the University of Pittsburgh School of Medicine. She completed a pediatric residency at Boston Children’s Hospital and a research fellowship in Neonatal-Perinatal Medicine with the Harvard Medical School Joint Program in Neonatology. She also earned a Master of Public Health in epidemiology from the Harvard School of Public Health.
In addition to clinical instruction and didactic teaching at several Harvard hospitals over several decades, Dr. Van Marter has been an adviser to pediatric residents and a research mentor to neonatology fellows and junior faculty. At the national level, she is a past chair of the American Academy of Pediatrics Section on Neonatal-Perinatal Medicine, and was a founder and mentor for its Trainees and Early Career Neonatologists Group that has fostered leadership development of individuals at early stages of their neonatology careers. She was elected to the Society for Pediatric Research, the Perinatal Research Society, and the American Pediatric Society.
Dr. Van Marter’s clinical research has focused on the epidemiology and treatment of bronchopulmonary dysplasia (BPD) and persistent pulmonary hypertension of the newborn (PPHN). Her work has contributed to the identification of several pregnancy-associated risk factors for PPHN and a greater understanding of clinical practices that may modify the risk for BPD in infants born before 29 weeks of gestation. She has been a principal investigator, site principal investigator and core director for numerous NIH and industry-funded studies. She has authored more than 70 papers published in peer-reviewed journals and has delivered many invited state-of-the-art and research talks at national and international conferences.